Tag: overreaction

  • Gilead Pullback a Potential Overreaction

    Gilead Pullback a Potential Overreaction

    Gilead (GILD) fell about 10%, or $8.86 on a disappointing cancer drug study. According to NBC, “The company did not significantly extend the lives of patients with certain lung cancer in a late-stage trial. The phase-three study was part of an effort to expand the use of Trodelvy, which is already approved to treat some…